Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Magnetic heart test could revolutionize heart attack diagnosis

NCT ID NCT05896826

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new, noninvasive device that uses ultra-sensitive magnetocardiography to detect heart attacks. Researchers will enroll nearly 4,000 healthy volunteers and chest pain patients to see if this magnetic scan can identify heart damage more accurately than current methods like EKGs and blood tests. The goal is to build a reliable diagnostic model that could lead to quicker, safer heart attack detection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetometer (device for magnetocardiography)
What this could lead to
If successful, this could provide a faster, more accurate way to diagnose heart attacks without needles or radiation.
What could go wrong
This is an early-stage study at one hospital, and the device's accuracy needs to be proven against existing tests. It may not work for all patients or be widely available soon.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 3,841 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

healthy individuals and chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination

Ages

18 to 79 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For healthy volunteers: Inclusion Criteria: 1. Age 18-79 years old; 2. No history of cardiovascular disease (coronary heart disease, structural heart disease, arrhythmia, heart failure, stroke, pulmonary embolism, aortic dissection, etc.), no cardiovascular risk factors (hypertension, diabetes, hyperlipidemia). For people over 65 years old, those with hypertension or hyperlipidemia, but with well-controlled blood pressure and lipid levels, taking no more than 2 drugs, and echocardiography showing no left ventricular hypertrophy, can be included; 3. The electrocardiogram is normal, and the cardiac ultrasound is basically normal in the past 1 year (mild valvular regurgitation can be included). 4. Sign the informed consent. Exclusion Criteria: 1. Those who with acute or chronic respiratory diseases; 2. Those who with obvious abnormality of liver or kidney function; 3. Those who with endocrine diseases such as abnormal thyroid function; 4. Those who with anemia or other blood diseases; 5. Those who with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.); 6. Those who are obese (BMI\>30kg/cm2) or underweight (BMI\<18kg/cm2); 7. Those who with malignant tumors; 8. Those who with infectious diseases or infectious diseases; 9. Those who with trauma or physical disability; 10. Those who with psychological or mental illness such as depression; 11. Those who are professional athletes, pregnant or breastfeeding women, alcoholics; 12. Those who are unable to perform magnetocardiography examination due to claustrophobia, etc., or those who fail to receive magnetocardiography examination; 13. Due to various reasons such as allergy to contrast agents, metal implants in vivo that are prohibited from performing 1.5T MRI (such as prostheses or steel plates implanted in orthopaedics, uterine contraceptive device) and other reasons, those who cannot or fail to cooperate with the corresponding research requirements. For chest pain patients who will receive ECG, biomarkers, or non-invasive imaging examination: Inclusion Criteria: 1. Age 18-79 years old; 2. Those with chest pain symptoms, diagnosed or highly suspected by the attending doctor or above as stable angina pectoris (SA), unstable angina pectoris (UA), non-ST segment elevation myocardial infarction (NSTEMI), ST segment elevation myocardial infarction (STEMI), and plan to receive electrocardiogram, biomarkers (high-sensitivity cardiac troponin, etc), or non-invasive imaging (cardiac magnetic resonance or single-photon-emission tomography); 3. Sign the informed consent. Exclusion Criteria: 1. Patients with known structural heart disease such as cardiomyopathy and valvular disease; 2. Patients with arrhythmias such as atrial fibrillation, supraventricular tachycardia, and atrioventricular block that have not returned to normal; 3. History of other cardiovascular diseases such as pulmonary embolism and aortic dissection; 4. Patients with connective tissue diseases (lupus erythematosus, rheumatoid arthritis, dermatomyositis, polyarteritis nodosa, etc.) combined with cardiac complications; 5. Obvious abnormal thyroid function, severe anemia or other blood diseases and other diseases that obviously affect the circulating blood supply; 6. Obese (BMI\>30kg/cm2) or underweight (BMI\<18kg/cm2); 7. Patients with malignant tumors; 8. Professional athletes, pregnant or breastfeeding women, alcoholics; 9. Acute diseases or critical illnesses in other systems, such as acute or severe respiratory diseases, abnormal liver function or renal function, etc.; 10. Patients with infectious diseases or infectious diseases; 11. Those who are unable or fail to perform magnetocardiography due to claustrophobia, physical impairment, etc.; 12. Unable to or fail to cooperate with the corresponding research requirements.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, 250012, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.